FDA warns Owlet Baby Care that its Smart Sock baby monitors are adulterated devices sold without marketing approval.
What happened
FDA reviewed Owlet's website, multiple commercial websites, and the firm's responses to FDA correspondence. It determined that the Owlet Smart Socks were offered for sale in the United States without FDA marketing approval, clearance, or authorization. Marketing examples captured on or about July 22-26, 2021 included claims to track a baby's oxygen level and heart rate and to notify users when readings leave preset zones.
What FDA found
Owlet marketed the Smart Socks in the United States without an FDA-approved premarket approval (PMA) or investigational device exemption (IDE), so FDA calls the devices adulterated.
21 U.S.C. § 351(f)(1)(B); 21 U.S.C. § 360e(a); 21 U.S.C. § 360j(g)The Smart Socks are devices because they are intended to diagnose or monitor oxygen desaturation and bradycardia and to alarm when readings are outside preset values.
21 U.S.C. § 321(h)Owlet did not have an approved premarket approval (PMA) application in effect for the Smart Socks as described and marketed.
21 U.S.C. § 360e(a)Owlet did not have an approved investigational device exemption (IDE) application for the Smart Socks as described and marketed.
21 U.S.C. § 360j(g)Introducing or delivering an adulterated or misbranded device into interstate commerce is prohibited.
21 U.S.C. § 331(a)
What FDA wants
FDA asks Owlet to stop any activities that adulterate the Smart Socks, including commercial distribution for the uses described. The firm must respond in writing within 15 business days of receiving the letter with the steps taken, corrective actions, and a timetable for any ongoing fixes.
Who should pay attention
- retailers selling baby monitors
- parents and caregivers using baby health monitors
- makers of consumer devices with medical claims
This is a summary. Read the original letter on fda.gov.